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Abstract
Introduction: Understanding the relationship between patient-reported osteoarthritis (OA) severity and other
patient-reported outcomes in the real-world clinical setting can provide a basis for appropriate patient
management. The objective of this study was to determine how patient-reported OA severity correlates with
patient-reported outcomes including pain, function and productivity.
Methods: We used the Adelphi Disease Specific Programme (DSP) for OA, a database aggregated from large,
multinational, observational studies for specific chronic diseases. Data were obtained based on a 0 to 100 mm pain
visual analogue scale (VAS) and a series of questions including functioning (that is, activities of daily living) and
work productivity. OA severity was rated by the patients based on the question “How bad would you say your
arthritis is now?” with potential responses of “mild,” “moderate,” and “severe.” Regression models and chi-square
analyses were used to evaluate the relationships between self-reported OA severity and other outcomes.
Results: Of 998 subjects in the OA DSP U.S. database, 714 (72.5%) agreed to participate. This sample was
predominantly female (61.7%) with a mean age of 63.8 ± 12.9 years. Increased OA severity was associated with an
older population (P < 0.05). With increasing OA severity (mild, moderate, severe), statistically significant differences
(P < 0.05) were observed in increased pain VAS scores (23.5, 50.2, 70.8, respectively), lower functioning outcomes,
and a higher percent of overall work impairment due to OA (17%, 37%, 48%, respectively). The increased work
impairment at greater severity levels also resulted in higher costs related to lost work productivity, with annual
costs due to lost productivity estimated at $6,096, $13,2510, and $17,214 per patient for self-reported mild,
moderate, and severe OA, respectively (P < 0.05 for pairwise comparisons).
Conclusions: In the clinical practice setting, patient-reported OA severity was associated with other key patient-
reported outcomes and thus may provide an accurate and tangible assessment of patients’ perceptions of their
disease. Identifying OA patients by their perceived severity level may be of benefit to patients and health-care
providers when choosing treatment options aimed at reducing pain, and improving function and productivity.
Introduction
Osteoarthritis (OA) is a degenerative joint disease that is
characterized pathologically by loss of articular cartilage
and concomitant development of osteophytes at the
joint margins, and characterized clinically by pain, stiff-
ness, fatigue, and functional impairment. These charac-
teristics result in the substantial disability and reduced
quality of life reported by patients with OA [1,2]. OA
has been estimated to occur in 27 million individuals in
the U.S. [3], and since age is the primary predictor, its
prevalence is likely to increase as the proportion of
older individuals in the population increases [4].
Although inflammation may occur, OA is not consid-
ered an inflammatory disease, and in the absence of
both a clearly defined etiology and the availability of dis-
ease-modifying drugs, recommendations for OA man-
agement have consistently focused on reducing pain and
improving function [5-9].
A variety of pharmacologic options are available for
managing OA-related pain such as simple analgesics,
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nonsteroidal anti-inflammatory drugs (NSAIDs), oral
corticosteroids, opioids, and injectables including corti-
costeroids and viscosupplementation with hyaluronan.
Choosing among these medications is often determined
by disease severity.
OA severity can be defined and graded using radio-
graphic and other objective techniques for assessing OA
pathology [10,11]. However, such severity may not cor-
relate with patients’ perceptions and therapeutic needs.
For example, Johnson et al. [12] showed that self-
reported improvement did not correlate with clinico-
pathologic findings including range of motion, disease
activity, and radiographic grade.
In clinical trials, definitions of severity are generally
based on cut-points for patient-reported pain, function,
and global assessments. Two studies using 0 to 10 pain
severity scales have suggested specific cut-points for
pain in patients with OA [13,14]. One study identified
the cut-points of 4 and 6 for patients with hip OA and
4 and 7 for those with knee OA [13], and the other
study suggested that scores of 5 and 7 were the optimal
cut-points [14]. However, in real world settings, categor-
izing patients as having mild, moderate, or severe dis-
ease based solely on pain cut-points may not necessarily
provide a comprehensive and accurate assessment of
OA severity from the patient’s perspective. Factors such
as functional impairment and worker productivity, while
substantially affected by the presence of pain and pain
exacerbations [15,16], may also contribute to a patient’s
overall perception of disease severity. A few orthopedic-
specific rating scales have been designed to assess func-
tional or physical limitations; however, they do not cate-
gorize severity levels to accurately guide physicians in
their evaluation and treatment of patients.
The ability to characterize OA severity and its asso-
ciated manifestations from the patient’s perspective may
provide a context within which management strategies
may be determined and therapeutic outcomes evaluated.
To our knowledge, there have been only limited
attempts to characterize levels of OA severity using
patient-based measures. These attempts have been
either specific to orthopedic procedures [17-19], or lack
the ability to measure patients’ expectations on a full
complement of disabilities [20-22].
A simple approach to establishing OA severity, with
applicability to the real-world clinical setting, is for
patients to self-rate their severity as mild, moderate, or
severe. However, asking just one question on severity of
OA needs to be supported by ascertaining whether such
reporting of severity correlates with (or manifests via)
other patient-reported outcomes that are interpretable,
useful, and quantifiable. The objective of this study was
to determine how several real-life parameters of patient
perceptions of OA severity levels correlate with patient-
reported pain, function, and productivity in clinical
practice.
Materials and methods
The Adelphi Disease Specific Programme (DSP) is a
database that is aggregated from large, multinational,
observational studies for specific chronic diseases [23].
The data were collected in clinical practice settings by
physicians who provided relevant information on
patients consulting for the disease of interest, with the
patients being invited to participate in answering self-
report questionnaires related to their symptoms, expec-
tations, and health status. The current analysis is based
on the DSP for OA for the year 2008 (OA DSP VII)
which included data for subjects from the U.S. As this
was a retrospective analysis of an existing dataset, local
ethics committee approval was not required.
Severity of OA was rated by the patients based on the
question “How bad would you say your arthritis is
now?” with potential responses of “mild,” “moderate,”
and “severe.” Patients also reported on their demo-
graphic and disease characteristics, and outcomes data
included a pain visual analogue scale (VAS; 0 to 100
with 0 = no pain and 100 = worst possible pain) to esti-
mate OA-related pain severity during the past week, and
questions on practical daily functioning that included
items on ability to perform both basic and instrumental
activities of daily living during the past week. These
questions were adapted from Lawton and Brody [24]
and scored on a 4-point Likert scale (1 = no difficulty, 2
= some difficulty, 3 = much difficulty, 4 = unable to do).
Additionally, data on productivity was captured using
the Work Productivity and Activity Impairment scale
(WPAI) [25]. The WPAI consists of six questions with
the first question on employment status. The remaining
five questions, referenced to the past seven days, pertain
to hours missed because of OA; hours missed because
of other reasons; hours actually worked; degree OA
affected productivity while working (rating scale from 0
= no effect to 10 = completely prevented from working);
and degree OA affected regular activities (rating scale 0
= no effect to 10 = completely prevented daily activ-
ities). By summing and dividing these responses accord-
ingly, the percent work time missed due to OA
(absenteeism) can be calculated, as well as the percent
impairment while on the job due to OA (presenteeism),
percent overall work impairments due to OA, and the
percent activity impairment due to OA. These percen-
tages were used to estimate the costs resulting from lost
productivity at each level of OA severity based on aver-
age hourly wages in 2008 for all employees, seasonally
adjusted, from the Bureau of Labor Statistics.
Descriptive analyses, regression models (adjusted for
age and gender, with patient-reported severity of OA as
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the predictor), and chi-square contingency tables were
used to evaluate the relationships between self-reported
OA severity and other self-reported outcomes in order
to quantify and construe their association with OA
severity levels. In addition, as an ancillary analysis, a
site-specific model was fit in which 10 binary variables,
one for each joint, were added (to age, gender, and
patient-reported severity of OA) along with the interac-
tion of each joint with severity of OA. All analyses were
pre-specified and performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA). Evidence for statistical
significance was based on a P-value less than 0.05.
Results
A total of 998 subjects were in the OA DSP database
from the U.S., and 71.5% (n = 714) agreed to participate.
The demographic and disease characteristics of these
714 subjects (Table 1) show that the sample was predo-
minantly female (61.7%), mean age was 63.8 ± 12.9
years, and 41% of patients were employed at least part-
time. The mean time since first OA diagnosis was 5.6 ±
6.5 years, and the knee was the joint most frequently
affected (72.4%). Severity of OA was rated as mild, mod-
erate and severe by 36.7%, 47.2% and 16.1% of the
714 patients, respectively.
Time since first diagnosis increased with increasing
OA severity: 4.6 years (95% confidence interval (CI): 3.8
to 5.3) for mild OA, 5.9 years (95% CI: 5.2 to 6.6) for
moderate OA, and 7.2 years (95% CI: 6.0 to 8.4) for
severe OA (P < 0.05 for each pairwise comparison
adjusted for age and gender). Similarly, after adjusting
for age and gender, increased age was associated with
greater OA severity levels (P < 0.0001 from chi-square
test; Figure 1). After adjustment for age and gender,
mean scores on pain severity increased as OA severity
increased: 23.5 (95% CI: 21.01 to 25.9) for mild OA,
50.2 (95% CI: 48.1 to 52.3) for moderate OA, and 70.8
(67.2, 74.4) for severe OA (P < 0.0001 for each pairwise
comparison).
Greater OA severity resulted in increased levels of
functional impairment, after adjustment for gender, as
manifested by patient report of increased difficulty in
performing a selected set of basic and instrumental
activities of daily living (Table 2). For every item of
functional ability, the difficulty score was greater than 1
at each OA severity level (lower bounds of the 95% con-
fidence intervals were greater than 1), and the greatest
difficulty was observed among patients who reported
severe OA. Pairwise comparisons between OA severity
levels additionally showed that differences in functional
abilities were statistically significant (P < 0.05).
A site-specific model was used to evaluate the rela-
tionship between patient-reported OA severity and func-
tional ability based on affected joints at three different
body sites (Table 3). Estimates from this model were
generally similar among the sites, and were also
Table 1 Demographic characteristics of the population
evaluated in the osteoarthritis Disease Specific Program
(N = 714)
Variable (number of observations) Value*
Mean age ± SD, years (n = 711) 63.8 ± 12.9
Age range, % (n = 711)
18 to 44 years 7.9
45 to 64 years 40.9
≥65 years 51.2
Gender, % (n = 711)
Female 61.7
Male 38.3
Employment, % (n = 674)






Mean time since diagnosis ± SD, years (n = 682) 5.6 ± 6.5











*Values and proportions are based on observed cases (that is, the number of
subjects who supplied data for each variable).
Figure 1 Relationship between self-reported osteoarthritis
severity and age. P < 0.05 for this relationship based on chi-square
analysis.
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comparable with the overall model presented in Table 2,
showing a trend with respect to an observed decrease in
functional ability with increasing OA severity.
Patient-reported OA severity was significantly (P <
0.0001) associated with employment status (Figure 2).
Higher proportions of unemployed patients reported
moderate and severe OA relative to those who were
employed (Figure 2a), and within each severity category,
the proportion of employed patients decreased as sever-
ity increased (Figure 2b).
For all questions evaluating the percent of OA-related
impairment of work and activity, increased impairment
was reported at greater OA severity levels (P < 0.05)
(Figure 3). All pairwise comparisons, adjusted for age
and gender, showed significant differences (P < 0.05) in
work impairment between OA severity levels except for
percent work time missed due to arthritis between mod-
erate and severe OA (P = 0.09).
Work impairment among employed individuals also
resulted in overall costs of $9,958 per patient per year
Table 2 Relationship between self-reported osteoarthritis severity and functional ability in performance of activities of
daily living
Functional measure Functional Score at Each Level of OA Severity
(95% confidence interval)*
Mild Moderate Severe
Basic activities of daily living
Dressing, including shoelaces and buttons 1.23 (1.16, 1.30) 1.44 (1.38, 1.50) 1.81 (1.70, 1.92)
Washing hair 1.13 (1.06, 1.20) 1.30 (1.25, 1.36) 1.53 (1.43, 1.63)
Rising from chair 1.34 (1.26, 1.41) 1.72 (1.65, 1.79) 2.11 (2.00, 2.23)
Getting in and out of bed 1.35 (1.27, 1.42) 1.70 (1.64, 1.76) 1.99 (1.88, 2.10)
Walking on flat ground 1.23 (1.16, 1.30) 1.59 (1.52, 1.65) 2.16 (2.05, 2.27)
Climbing five steps 1.43 (1.34, 1.51) 2.04 (1.96, 2.11) 2.49 (2.37, 2.62)
Washing and drying 1.09 (1.03, 1.15) 1.25 (1.20 (1.30) 1.52 (1.43, 1.60)
Taking a bath 1.23 (1.13, 1.32) 1.48 (1.40, 1.56) 1.92 (1.78, 2.06)
Toileting 1.17 (1.11, 1.24) 1.55 (1.49, 1.61) 1.88 (1.78, 1.98)
Instrumental activities of daily living
Shopping 1.20 (1.13, 1.28) 1.56 (1.49, 1.62) 2.04 (1.92, 2.15)
Getting in and out of a car 1.25 (1.83, 1.33) 1.73 (1.67, 1.79) 2.15 (2.04, 2.26)
Performing chores (for example, vacuuming or gardening) 1.39 (1.30, 1.48) 2.00 (1.92, 2.08) 2.64 (2.50, 2.77)
Response options: 1-without any difficulty, 2-with some difficulty, 3-with much difficulty, 4-unable to do.
*All pairwise comparisons of arthritis severity categories were statistically significant (P < 0.05).
Table 3 Relationship between self-reported osteoarthritis (OA) severity and functional ability in performance of
activities of daily living among patients with affected joints at three different body sites
Functional measure Functional Score at Each Level of OA Severity
Mild Moderate Severe
Knees Hips Wrists Knees Hips Wrists Knees Hips Wrists
Basic activities of daily living
Dressing, including shoelaces and buttons 1.28 1.31 1.43 1.60 1.68 1.70 2.22 2.08 1.97
Washing hair 1.20 1.17 1.26 1.49 1.63 1.55 2.01 1.89 1.94
Rising from chair 1.54 1.55 1.50 1.67 1.64 1.63 2.37 2.17 2.20
Getting in and out of bed 1.52 1.57 1.49 1.67 1.77 1.69 2.18 2.14 2.14
Walking on flat ground 1.39 1.48 1.32 1.51 1.52 11.48 2.29 2.05 2.12
Climbing five steps 1.62 1.60 1.45 1.91 1.96 1.78 2.65 2.49 2.57
Washing and drying 1.08 1.04 1.09 1.29 1.47 1.46 1.84 1.83 1.79
Taking a bath 1.42 1.33 1.41 1.68 1.79 1.73 2.08 1.98 2.05
Toileting 1.34 1.32 1.33 1.50 1.55 1.48 2.11 1.99 2.01
Instrumental activities of daily living
Shopping 1.33 1.29 1.23 1.52 1.55 1.45 2.20 1.99 2.20
Getting in and out of a car 1.42 1.46 1.35 1.61 1.69 1.67 2.37 2.17 2.24
Performing chores (for example, vacuuming or gardening) 1.37 1.42 1.34 1.82 1.91 1.93 2.96 2.80 2.90
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resulting from lost productivity. When stratified by self-
reported OA severity after adjusting for age and gender,
lost productivity costs were significantly higher with
increasing levels of severity. These costs were estimated
at $6,096 per year for a patient with mild severity,
$13,251 for moderate OA severity, and $17,214 for a
patient with severe OA (Figure 4, P < 0.05 for all pair-
wise comparisons).
Discussion
We can consider that defining disease severity from the
patient’s perspective may be a relevant strategy for the
daily clinical management of patients with OA. For such
a strategy to be effective, it is important to establish that
levels of patient-reported disease severity do in fact
demonstrate a relationship with disease-related out-
comes. This study indicated that patients with OA who
reported their disease severity as being mild, moderate,
or severe, also reported correspondingly greater levels of
pain, functional impairment, and productivity impair-
ment. For each increasing level of OA severity, the cor-
responding magnitude of the outcome was significantly
and typically different from that reported for the other
OA severity levels, with pain, function, and work pro-
ductivity most impacted in patients who rated their OA
as severe.
Pain and function are core symptomatic outcomes of
OA that are frequently targeted as part of pharmacolo-
gic therapy, and it may be expected that these outcomes
are associated with patient perceptions of OA severity.
Figure 2 Relationship between self-reported osteoarthritis (OA) severity and current employment status. (a) Patient-reported OA severity
stratified by employment status. P < 0.0001 based on chi-square analysis. (b) Proportion of patients at each OA severity level who reported
being employed.
Figure 3 Relationship between self-reported osteoarthritis (OA) severity and productivity. Evaluation of productivity based on the Work
Productivity and Activity Impairment (WPAI) questionnaire [25]. CI, confidence interval. Values of means of percent impairment were adjusted for
age and gender. *P < 0.05 for pairwise comparisons between severity levels.
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However, it was also of particular interest to note that
the results for productivity were in accord with the
other outcomes, since a previous study suggested an
association among pain, function, and economic produc-
tivity in patients with OA [16]. In the current study, not
only did productivity show a significant association with
severity, with pairwise comparisons between severity
categories demonstrating statistical significance for vir-
tually all WPAI items, but the interference with produc-
tivity was substantial in patients with severe OA. At this
level of severity, approximately three-quarters of the
patients (74.1%) reported being unemployed, and for
those who were employed there was 42% impairment
while working, and overall working impairment was
47%. These data are consistent with published reports
that productivity losses substantially contribute to the
economic burden of OA [26-29], despite the fact that
OA is more prevalent in an older population who may
not necessarily be expected to be employed.
This study also suggests that there are substantial
indirect costs related to lost productivity in a patient
with OA (mean costs of $9,958 per year). Importantly,
these costs were significantly higher at greater OA
severity with the annual cost for a patient with severe
OA almost three times that of a patient with mild OA.
These results are not only important from the economic
perspective, but offer further evidence that the patient’s
perception of OA severity may facilitate assessment of
functional and economic outcomes.
In contrast to other available measures [20,22,30],
patients were asked to characterize their OA severity
and we then evaluated the association between their
response and external measures. Although such an
approach does not enable a quantitative measure of
severity, it provides a patient-based perspective that
demonstrates significant associations with other patient-
reported outcomes.
It should also be noted that this study focused on the
associations between a simple patient-reported assess-
ment of OA severity and other patient-reported out-
comes. While the goal was to enhance our understanding
of OA by relating patients’ perceptions of severity to
other measures of interest, it also provides insight into
what it means from the patient’s perspective to have
mild, moderate, or severe OA.
A similar patient-based perspective in patients with
OA was evaluated in a study by Reichmann et al. [31]
in which patients were asked to rate their overall health
status as excellent, very good, fair, or poor. Our assess-
ment was based on a question that asked patients to
specifically rate their OA severity as mild, moderate, or
severe. Patients with OA are generally characterized by
a substantial presence of comorbid conditions, some of
which are associated with additional disability and func-
tional limitations [32,33]. Thus, the generic question on
overall health status is expected to encompass a multi-
tude of factors including but not restricted to the
patient’s OA.
While in the present study it cannot be totally
excluded that patients may have considered other fac-
tors to some extent when rating their OA severity, the
presence of comorbidities would be expected to contri-
bute substantially, to a large extent, to patients’ percep-
tions of their health status. In fact, Reichmann et al.
found that, among patients with knee OA, self-reported
health status was associated with comorbidity and, in
addition, functional status. Although a moderate asso-
ciation between patient-rated OA severity and patient-
rated general health status is also to be expected, we
believe that such a correlation will not be large as
patient-reported OA severity (though related to) is dis-
tinct from patient-reported general health status, and
represents a measure that may be useful in the clinical
setting for enabling disease-specific treatment decisions.
Figure 4 Relationship between self-reported osteoarthritis severity and mean overall cost of lost productivity per patient per year.
P < 0.05 for all pairwise comparisons.
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Importantly, this investigation is not a validation study
and does not attempt to provide detailed psychometric
evaluation of the assessment under consideration, a sub-
ject that is beyond the scope of this research and the
data presented. Similarly, no cause-and-effect relation-
ships can be drawn from this cross-sectional observa-
tional study, and findings are limited to the strength
and magnitude of the observed associations.
Several limitations of this study should be considered,
including the fact that it was based on physicians’ and
patients’ agreement to participate. It is possible that
individuals who participated may have characteristics
and perceptions different from those who refused to
participate, thereby introducing selection bias and redu-
cing the generalizability. The introduction of recall bias
is also a common limitation of many studies based on
questionnaires. However, this bias was minimized by
using questions with a maximum recall period of the
past seven days. While the cross-sectional nature of
DSPs precludes any causation, no cause and effect
imputation was made for the ratings of severity of either
OA severity or other outcomes. Any relationships
should be considered associative rather than causal.
That neither the type of employment nor the specific
site of diagnosed OA were captured in the questionnaire
may also be considered a limitation, since the former is
likely to affect the absolute magnitude of productivity
loss, and the latter is likely to variously affect functional-
ity with regard to activities of daily living. In lieu of a
site-specific OA diagnosis, an analysis of function was
performed based on affected joints, and was observed to
be consistent with the overall model. However, it should
be noted that the site-specific results should be inter-
preted cautiously; the number of variables complicates
the model and its interpretation, and the presence of
multiple affected joints in a proportion of patients is
also likely a confounding factor. Further evaluation of
OA severity based on these variables would provide
interesting supplementary information on the relation-
ship between OA severity and outcomes.
Another limitation is that we did not control for the
potential effects of comorbid conditions on the patient’s
perception of OA disease severity. However, the consis-
tency of results across outcomes, including the narrow
range of variance, suggests that this impact was low. With
regard to the diagnosis of OA for inclusion, this diagnosis
is dependent on the diagnostic skill of the treating physi-
cian, and it is therefore possible that misdiagnosis may
have occurred in a small proportion of the sample popula-
tion. This study could also be criticized for not comparing
patient-reported severity with radiographic results. How-
ever, radiographic observations are physician-reported
outcomes and their practicality for making clinical treat-
ment decisions such as for knee replacement is unclear
and may be better determined by functional status and
patient preferences [34]. Nevertheless, demonstrating
whether an association exists between radiographic and
patient-reported OA severity can help confirm the value
of using patient-reported assessment.
Despite these limitations, we suggest that the
approach described here enables a rapid assessment of
OA severity that may be of value in the clinical setting
for providing an accurate, appropriate, and quantifiable
measurement of the patient’s perceived health status,
especially with respect to symptoms. This metric pro-
vides a practical comparison, utilizable among practice
specialties (family practice, rheumatology, orthopedics,
and so on), for providing a better understanding of how
patient’s may perceive changes in their OA severity.
Additionally, for second and third party payers, it may
potentially provide a measure of efficacy on patients’
risk pool for future disease expectations. A more rigor-
ous evaluation of this technique will also help integrate
the patient’s perspective into an overall definition of OA
severity.
Conclusions
The significant associations between self-reported OA
severity and other patient-reported outcomes indicate
the clinical relevancy of asking patients to self-evaluate
their OA severity. This simple and direct approach for
determining OA severity represents a practical solution
in the clinical setting that may benefit health care provi-
ders when choosing treatment options aimed at redu-
cing pain and improving patient function and work
productivity. Further analyses of these relationships and
evaluation of patient-reported severity with other clini-
cally relevant criteria may help confirm the utility of
this method of defining and assessing OA severity in
clinical practice.
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